Trade Report: The Greatmark Investment Partners Inc. Sold shares of Core Laboratories NV (CLB)

The Greatmark Investment Partners Inc. Sold shares of Core Laboratories NV (CLB)

Greatmark Investment Partners Inc. cut its stake in Core Laboratories NV (NYSE:CLB) by 9.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,940 shares of the company’s stock after selling 895 shares during the period. Greatmark Investment Partners Inc.’s holdings in Core Laboratories NV were worth $1,108,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital Fund Management S.A. purchased a new position in Core Laboratories NV during the second quarter valued at about $12,650,000. Geode Capital Management LLC raised its position in Core Laboratories NV by 4.1% in the first quarter. Geode Capital Management LLC now owns 227,422 shares of the company’s stock valued at $25,549,000 after buying an additional 8,979 shares in the last quarter. AMP Capital Investors Ltd raised its position in Core Laboratories NV by 47.1% in the first quarter. AMP Capital Investors Ltd now owns 19,665 shares of the company’s stock valued at $2,248,000 after buying an additional 6,300 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in Core Laboratories NV by 2.5% in the first quarter. TIAA CREF Investment Management LLC now owns 36,509 shares of the company’s stock valued at $4,104,000 after buying an additional 876 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its position in Core Laboratories NV by 22.4% in the second quarter. Eagle Asset Management Inc. now owns 28,826 shares of the company’s stock valued at $3,571,000 after buying an additional 5,271 shares in the last quarter.

Core Laboratories NV (NYSE:CLB) traded down 0.74% during mid-day trading on Monday, hitting $110.59. 313,245 shares of the stock were exchanged. The company has a 50-day moving average price of $110.58 and a 200-day moving average price of $117.47. Core Laboratories NV has a one year low of $84.50 and a one year high of $135.49. The company has a market cap of $4.88 billion, a P/E ratio of 58.67 and a beta of 1.45.

Core Laboratories NV (NYSE:CLB) last issued its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.35. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The company had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. During the same period last year, the firm posted $0.81 EPS. Core Laboratories NV’s revenue for the quarter was down 27.4% on a year-over-year basis. Analysts forecast that Core Laboratories NV will post $1.54 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 22nd. Shareholders of record on Friday, October 21st will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.99%. The ex-dividend date of this dividend is Wednesday, October 19th. Core Laboratories NV’s payout ratio is currently 117.65%.

CLB has been the topic of several analyst reports. Citigroup Inc. cut their price target on shares of Core Laboratories NV from $118.00 to $116.00 and set a “neutral” rating on the stock in a report on Monday, September 12th. Zacks Investment Research downgraded shares of Core Laboratories NV from a “buy” rating to a “hold” rating in a research note on Monday, September 26th. Loop Capital initiated coverage on shares of Core Laboratories NV in a research note on Friday, September 30th. They set a “hold” rating and a $120.00 price objective for the company. DA Davidson initiated coverage on shares of Core Laboratories NV in a research note on Wednesday, October 5th. They set a “buy” rating and a $136.00 price objective for the company. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Core Laboratories NV in a research note on Thursday, June 30th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. Core Laboratories NV presently has a consensus rating of “Hold” and an average target price of $121.61.

Core Laboratories NV Company Profile

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Related posts

Leave a Comment